As knockdown of USP26 potently activated the TGF‐β pathway in breast cancer, we investigated whether depletion of USP26 in the TGF‐β‐responsive metastatic cell line MDA‐MB‐231 enhanced cellular motility and invasion. Here, USP26 is linked to breast carcinoma.